Showing results (121-130 of 223) with videos related to

Sort By:
Pageof 23
British Journal of Haematology|December 2, 2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphomaLuca Arcaini, Thierry Lamy, Jan Walewski, et al.
Blood|April 18, 2012
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetJoëlle Guilhot, Michele Baccarani, Richard E Clark, et al.
Trials|January 3, 2023
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesMax Topp, Monika Dlugosz-Danecka, Aleksander B Skotnicki, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Leukemia & Lymphoma|March 19, 2024
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trialVikas Gupta, Stephen Oh, Timothy Devos, et al.
Leukemia & Lymphoma|June 7, 2017
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>.</sup>Tadeusz Robak, Huiqiang Huang, Jie Jin, et al.
British Journal of Haematology|April 11, 2019
Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patientsAdam Folta, Martin Culen, Ivana Jeziskova, et al.
Epigenetics|March 25, 2022
Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of <i>WNT5A</i> promoter and undetectable expression of <i>WNT5A</i> geneLucie Poppova, Sarka Pavlova, Beatriz Gonzalez, et al.
Haematologica|April 13, 2019
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cellsMiroslav Boudny, Jana Zemanova, Prashant Khirsariya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN StudyBruce D Cheson, Neil Chua, Jiri Mayer, et al.
Pageof 23